Isomorphic Labs opened 2024 with two small-molecule research collaborations, with Eli Lilly and with Novartis.

Both collaborations are multi-target and focused on small molecules, combining upfront and milestone payments. Lilly paid $45 million upfront and Novartis $37.5 million upfront. Isomorphic says the two deals could be worth nearly $3 billion excluding royalties. The page names no specific models or targets.

Isomorphic Labs is an AI drug design company spun out of Google DeepMind, running small-molecule research collaborations with Lilly, Novartis and Johnson & Johnson.

This sits in the Design & Stress-Test stage of the AI use-case lifecycle: Named examples from the tools pharma teams use to scope, prototype and benchmark an AI use case before committing to build it — data-catalog, sandbox and evaluation platforms.